Mastitis can mean the difference between making or losing money1
A 2018 Canadian study concluded that2:
- Total mastitis costs represented $662 per milking cow per year ($66,178/100 cows-year) for a typical dairy farm, with a maximum of $1,826.
- A clinical mastitis case for the median herd in the study amounted to $744, but varied from $50 to $5,349.
Orbeseal is effective in preventing intramammary infection at dry‑off
- OrbeSeal® is the only internal teat sealant that can state its reputation for efficacy on over 40 years of peer reviewed studies worldwide, with significant Canadian contribution, including the latest meta-analyses, published in 20193.
2010 canadian study4
- 25% reduction of risk of clinical mastitis when comparing OrbeSeal® + ADCT (antibiotic dry-cow therapy) to ADCT alone.
Prevent clinical coliform mastitis in your dairy herd with enviracor® j‑5
Almost 1 in 4 cows suffer from clinical mastitis each lactation cycle and coliform bacteria are frequently the cause5.
- While causing pain and adversely affecting milk production, clinical coliform mastitis can also lead to the loss of a quarter, an increase in culls, and be the cause of animal death.
Vaccinate your herd against clinical coliform mastitis with enviracor® j‑5
A 3-dose vaccination program with Enviracor J‑5 leads to:
- Up to an 80% reduction in clinical coliform mastitis6,7,8.
- Up to a 41% reduction in the duration of clinical mastitis in cows that get sick9.
- Extended protection throughout the first 100 days of lactation6,7,8.
- Ontario Dairy Farm Accounting Project. Annual Report 2018. A co-operative project of Canadian Dairy Commission Dairy Farmers of Ontario. Released July 2019. https://www.milk.org/Corporate/pdf/Publications-ODFAPReport.pdf
- Aghamohammadi M, Haine D, Kelton DF, et al. Herd-level mastitis-associated costs on Canadian dairy farms. Frontiers in Veterinary Science 2018;5:100.
- Dufour S, Wellemans V, Roy J, et al. Non-antimicrobial approaches at drying-off for treating and preventing intramammary infectionsin dairy cows. Part 1. Meta-analyses of efficacy of using an internal teat sealant without a concomitant antimicrobial treatment. Animal Health Research Reviews 2019;1-12.
- Baillargeon P, LeBlanc SJ. Clinical and economic effects of an internal teat sealant at dry-off on the incidence of clinical mastitis in early lactation. Bovine Pract 2010;(44):1-11.
- Olde Riekerink RGM, Barkema HW, Kelton DF, Scholl DT. 2008. Incidence Rate of Clinical Mastitis on Canadian Dairy Farms. J Dairy Sci. 91:1366-1377.
- Gonzalez RN, Cullor JS, Jasper DE, et al. 1989. Prevention of clinical coliform mastitis by a mutant Escherichia coli vaccine. Can J Vet Res. 53(3):301-305.
- Hogan JS, Smith KL, Todhunter DA, Schoenberger PS. 1992. Field trial to determine efficacy of an Escherichia coli J5 mastitis vaccine.J Dairy Sci. 75:78-84.
- Gonzalez RN, Wilson D, Muhammed H. 1996. A placebo-controlled trial of an Escherichia coli J5 bacterin and the ribotyping-based assessment of coliform bacteria diversity on a dairy farm. Proc. 19th World Buiatrics Congress, Edinburgh:277-280.
- Alaniz GR, Meinert TR, Loveland WJ, et al. 2013. Evaluation of Escherichia coli Bacterin, J‑5 Strain, as an Aid in the Control of Clinical Signs Associated with E. coli Mastitis in Dairy Cows. Proc. 52nd National Mastitis Council annual meeting, San Diego:199-200.